Comparative Pharmacology
Head-to-head clinical analysis: ONGLYZA versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONGLYZA versus SITAGLIPTIN AND METFORMIN HYDROCHLORIDE.
ONGLYZA vs SITAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing incretin hormones (GLP-1, GIP) to enhance glucose-dependent insulin secretion and suppress glucagon release.
Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), enhancing insulin secretion and suppressing glucagon release in a glucose-dependent manner. Metformin is a biguanide that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves insulin sensitivity.
2.5 mg or 5 mg orally once daily
Oral, initial dose based on prior therapy and glycemic control: 50 mg sitagliptin / 500 mg metformin twice daily or 50 mg sitagliptin / 1000 mg metformin twice daily. Max sitagliptin 100 mg/day, metformin 2000 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 12.4 hours for saxagliptin. The half-life of its active metabolite is about 2.1 hours. The pharmacologically relevant half-life supports once-daily dosing.
Metformin: Terminal half-life ~6.2 hours (plasma), but prolonged to ~17.6 hours in renal impairment; clinical context: dosing interval adjusted for CrCl. Sitagliptin: Terminal half-life ~12.4 hours, allows once-daily dosing.
Approximately 75% of the administered dose is excreted in urine, with about 21% recovered as parent drug, and the remainder as metabolites. Fecal excretion accounts for about 22% of the dose, primarily as parent drug and metabolites.
Metformin: 90% renal unchanged (active tubular secretion), 10% fecal. Sitagliptin: 87% renal (active tubular secretion), 13% fecal (biliary excretion minimal for sitagliptin, but fecal includes unabsorbed drug).
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor